Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1ФГБОУ ВО «Ставропольский государственный медицинский университет» Минздрава России. 355017, Россия, Ставрополь, ул. Мира, д. 310; 2Университет им. Давида Бен-Гуриона в Негеве. 8410501, Израиль, Беер-Шева
Список исп. литературыСкрыть список 1. Арана Д, Розенбаум Д. Фармакотерапия психических расстройств. Пер. с англ. под ред. С.Н.Мосолова. М.: БИНОМ. Лаборатория знаний, 2004. / Arana D, Rozenbaum D. Farmakoterapiia psikhicheskikh rasstroistv. Per. s angl. pod red. S.N.Mosolova. M.: BINOM. Laboratoriia znanii, 2004. [in Russian] 2. Васильева А.В. и др. Применение спитомина (буспирон) в комбинированной терапии панического расстройства. Журн. неврологии и психиатрии им. C.C.Корсакова. 2015; 115 (11): 63–71. / Vasil'eva A.V. i dr. Primenenie spitomina (buspiron) v kombinirovannoi terapii panicheskogo rasstroistva. Zhurn. nevrologii i psikhiatrii im. C.C.Korsakova. 2015; 115 (11): 63–71. [in Russian] 3. Дамулин И.В., Суворова И.А. Современная концепция повышения эффективности терапии антидепрессантами. Журн. неврологии и психиатрии им. C.C.Корсакова. 2015; 115 (3): 106–12. / Damulin I.V., Suvorova I.A. Sovremennaia kontseptsiia povysheniia effektivnosti terapii antidepressantami. Zhurn. nevrologii i psikhiatrii im. C.C.Korsakova. 2015; 115 (3): 106–12. [in Russian] 4. Дзампаев А.Т., Суворова И.А., Дамулин И.В. Клинический потенциал и перспективы применения препарата буспирон в терапии тревожных расстройств. Журн. неврологии и психиатрии им. C.C.Корсакова. 2014; 114 (8): 94–104. / Dzampaev A.T., Suvorova I.A., Damulin I.V. Klinicheskii potentsial i perspektivy primeneniia preparata buspiron v terapii trevozhnykh rasstroistv. Zhurn. nevrologii i psikhiatrii im. C.C.Korsakova. 2014; 114 (8): 94–104. [in Russian] 5. Дробижев М.Ю. и др. Рациональный выбор препарата на основе представлений о патогенезе психического расстройства и механизме его действия. Журн. неврологии и психиатрии им. C.C.Корсакова. Спецвып. 2014; 114 (11): 15–21. / Drobizhev M.Iu. i dr. Ratsional'nyi vybor preparata na osnove predstavlenii o patogeneze psikhicheskogo rasstroistva i mekhanizme ego deistviia. Zhurn. nevrologii i psikhiatrii im. C.C.Korsakova. Spetsvyp. 2014; 114 (11): 15–21. [in Russian] 6. Инструкция по медицинскому применению препарата спитомин (буспирон), 2014. / Instruktsiia po meditsinskomu primeneniiu preparata spitomin (buspiron), 2014. [in Russian] 7. Левин О.С. Применение буспирона в клинической практике. Журн. неврологии и психиатрии им. C.C.Корсакова. 2015; 115 (4): 83–7. / Levin O.S. Primenenie buspirona v klinicheskoi praktike. Zhurn. nevrologii i psikhiatrii im. C.C.Korsakova. 2015; 115 (4): 83–7. [in Russian] 8. Alfieri AB, Cubeddu LX. Comparative efficacy of a single oral dose of ondansetron and of buspirone against cisplatin-induced emesis in cancer patients. Br J Cancer 1995; 72 (4): 1013–5. 9. Allen LE, Ferguson HC, Kissel JW. Psychosedative agents. 2. 8-(4-Substituted 1-piperazinylalkyl)-8-azaspiro (4.5) decane-7, 9-diones. J Med Chem 1972; 15 (5): 477–9. 10. Apter JT, Allen LA. Buspirone: future directions. J Clin Psychopharmacol 1999; 19 (1): 86–93. 11. Bailey DG, Dresser G, Arnold JMO. Grapefruit-medication interactions: forbidden fruit or avoidable consequences? Can Med Assoc J 2013; 185 (4): 309–16. 12. Baldwin DS et al. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2005; 19 (6): 567–96. 13. Bech P et al. Outcomes on the pharmacopsychometric triangle in bupropion‐SR vs. buspirone augmentation of citalopram in the STAR* D trial. Acta Psychiatr Scand 2012; 125(4): 342–8. 14. Becker C, Hamon M, Benoliel JJ. Prevention by 5-HT1A receptor agonists of restraint stress-and yohimbine-induced release of cholecystokinin in the frontal cortex of the freely moving rat. Neuropharmacology 1999; 38 (4): 525–32. 15. Berger A et al. Magnitude of potentially inappropriate prescribing in Germany among older patients with generalized anxiety disorder. BMC Geriatr 2009; 9 (1): 31. 16. Bergman H et al. Systematic review of interventions for treating or preventing antipsychotic-induced tardive dyskinesia. Health Technol Assess 2017; 21 (43): 1–248. 17. Bernardy NC et al. Prescribing trends in veterans with posttraumatic stress disorder. J Сlin Psychiatry 2012; 73 (3): 297–303. 18. Blaisdell GD. Akathisia: a comprehensive review and treatment summary. Pharmacopsychiatry 1994; 27 (4): 139–46. 19. Blier P, Ward NM. Is there a role for 5-HT1A agonists in the treatment of depression? Biol Psychiatry 2003; 53 (3): 193–203. 20. Bonhaus DW et al. RS-102221: a novel high affinity and selective, 5-HT2C receptor antagonist. Neuropharmacology 1997; 36 (4): 621–9. 21. Bostwick JM, Jaffee MS. Buspirone as an antidote to SSRI-induced bruxism in 4 cases. J Clin Psychiatry 1999; 60 (12): 857–60. 22. Brahm NC, Fast GA, Brown RC. Buspirone for autistic disorder in a woman with an intellectual disability. Ann Pharmacother 2008; 42 (1): 131–7. 23. Buspirone monograph. Drugs.com. 1986. FDA Approval Committee. 24. Campbell BCA et al. Interventions for treating anxiety after stroke. Cochrane Database Syst Rev 2011; 12: CD008860. 25. Chamberlain SR et al. Lack of deleterious effects of buspirone on cognition in healthy male volunteers.J Psychopharmacol 2007; 21 (2): 210–5. 26. Chessick CA et al. Azapirones for generalized anxiety disorder. Cochrane Database Syst Rev (Online) 2006; 3: CD006115. 27. Chiodera P et al. Different effects of the serotonergic agonists buspirone and sumatriptan on the posterior pituitary hormonal responses to hypoglycemia in humans. Neuropeptides 1996; 30 (2): 187–92. 28. Chugani DC et al. Efficacy of low-dose Buspirone for restricted and repetitive behavior in young children with autism spectrum disorder. A Randomized Trial. J Pediatr 2016; 170: 45–53, e1–4. 29. Clayton AH et al. Sexual dysfunction associated with major depressive disorder and antidepressant treatment. Exp Opinion Drug Saf 2014; 13 (10): 1361–74. 30. Çolak Sivri R, Akça ÖF. Buspirone in the Treatment of Fluoxetine-Induced Sleep Bruxism. J Child Adolesc Psychopharmacol 2016; 26 (8): 762–3. 31. Cottraux J et al. A controlled study of cognitive behaviour therapy with buspirone or placebo in panic disorder with agoraphobia. Br J Psychiatr 1995; 167 (5): 635–41. 32. Davari-Ashtiani R et al. Buspirone versus methylphenidate in the treatment of attention deficit hyperactivity disorder: a double-blind and randomized trial. Child Psychiatry Hum Dev 2010; 41 (6): 641–8. 33. Davidson JR et al. Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. J Сlin Psychiatry 1999; 60 (8): 528. 34. Dimitriou EC, Dimitriou CE. Buspirone augmentation of antidepressant therapy. J Сlin Psychopharmacol 1998; 18 (6): 465. 35. D'Mello DA, McNeil JA, Harris W. Buspirone suppression of neuroleptic-induced akathisia: multiple case reports. J Сlin Psychopharmacol 1989; 9 (2): 151–2. 36. Duffy JD, Malloy PF. Efficacy of buspirone in the treatment of posttraumatic stress disorder: an open trial. Ann Clinical Psychiatry 1994; 6 (1): 33–7. 37. Duggal HS et al. Sertraline and buspirone in adolescent delusional body dysmorphic disorder. Indian J Psychiatr 2001; 43 (4): 370–1. 38. Durst R et al. Kleptomania: phenomenological, clinical and legal aspects. Harefuah 1997; 33 (10): 441–4, 502–3. 39. Durst R, Katz G, Knobler HY. Buspirone augmentation of fluvoxamine in the treatment of kleptomania. J Nerv Ment Dis 1997; 185 (9): 586–7. 40. Dursun SM, Burke JG, Reveley MA. Buspirone treatment of Tourette's syndrome. Lancet 1995; 345 (8961): 1366–7. 41. Fang Y et al. A pilot study of the efficacy and safety of paroxetine augmented with risperidone, valproate, buspirone, trazodone, or thyroid hormone in adult Chinese patients with treatment-resistant major depression. J Clin Psychopharmacol 2011; 31 (5): 638–42. 42. Fava M. The combination of buspirone and bupropion in the treatment of depression. Psychother Psychosom 2007; 76 (5): 311–2. 43. Fayyazi A et al. A Comparison of Risperidone and Buspirone for Treatment of Behavior Disorders in Children with Phenylketonuria. Ir J Child Neurology 2014; 8 (4): 33–8. 44. Fichtner CG, Crayton JW. Buspirone in combat-related posttraumatic stress disorder. J Clin Psychopharmacol 1994; 14 (1): 79–81. 45. Fukai M et al. Oxytocin effects on emotional response to others' faces via serotonin system in autism: A pilot study. Psychiatry Res 2017; 267: 45–50. 46. Gammans RE, Mayol RF, Labudde JA. Metabolism and disposition of buspirone. Am J Med 1986; 80 (3): 41–51. 47. Ghaleiha A et al. A double-blind, randomized, and placebo-controlled trial of buspirone added to risperidone in patients with chronic schizophrenia. J Clin Psychopharmacol 2010; 30 (6): 678–82. 48. Ghanizadeh A, Ayoobzadehshirazi A. A randomized double-blind placebo-controlled clinical trial of adjuvant buspirone for irritability in autism. Pediatr Neurol 2015; 52 (1): 77–81. 49. Goff DC et al. An open trial of buspirone added to neuroleptics in schizophrenic patients. J Сlin Psychopharmacol 1991; 11 (3): 193–7. 50. Goldberg HL. Buspirone – a new antianxiety agent not chemically related to any presently marketed drugs (proceedings). Psychopharmacol Bull 1979; 15 (2): 90–2. 51. Grady TA et al. Double-blind study of adjuvant buspirone for fluoxetine-treated patients with obsessive-compulsive disorder. Am J Psychiatry 1993; 150: 819. 52. Green TR. Bupropion for SSRI-induced fatigue. J Clin Psychiatry 1997; 58 (4): 174. 53. Gross MD. Buspirone in ADHD with ODD. J Am Acad Child Adolescent Psychiatry 1995; 34 (10): 1260. 54. Halaby A, Haddad R, Naja W. Non-Antidepressant Treatment of Social Anxiety Disorder: A Review. Curr Clin Pharmacology 2015; 10 (2): 126–30. 55. Hamik A et al. Analysis of tandospirone (SM-3997) interactions with neurotransmitter receptor binding sites. Biol Psychiatry 1990; 28 (2): 99–109. 56. Hamner M, Ulmer H, Horne D. Buspirone potentiation of antidepressants in the treatment of PTSD. Depress Anxiety 1997; 5 (3): 137–9. 57. Harvey KV, Balon R. Augmentation with buspirone: a review. Ann Clin Psychiatry 1995; 7 (3): 143–7. 58. Herrmann N, Eryavec G. Buspirone in the management of agitation and aggression associated with dementia. Am J Geriatr Psychiatry 1993; 1 (3): 249–53. 59. Holttum JR, Lubetsky MJ, Eastman LE. Comprehensive management of trichotillomania in a young autistic girl. J Am Acad Child Adolesc Psychiatry 1994; 33 (4): 577–81. 60. Howland RH. Buspirone: back to the future. J Psychosoc Nurs Ment Health Servic 2015; 53 (11): 21–4. 61. Itzhak Y, Ruhland M, Krähling H. Binding of umespirone to the σ receptor: Evidence for multiple affinity states. Neuropharmacology 1990; 29 (2): 181–4. 62. Jacobsen FM. Possible augmentation of antidepressant response by buspirone. J Clin Psychiatry 1991; 52 (5): 217–20. 63. Jann MW. Buspirone: an update on a unique anxiolytic agent. Pharmacotherapy: J Hum Pharmacol Drug Ther 1988; 8 (2): 100–16. 64. Kranke P et al. Intravenous buspirone for the prevention of postoperative nausea and vomiting. Euro J Clin Pharmacol 2012; 68 (11): 1465–72. 65. Kuloglu M, Ekinci O, Caykoylu A. Venlafaxine-associated nocturnal bruxism in a depressive patient successfully treated with buspirone. J Psychopharmacol 2010; 24 (4): 627–8. 66. Landen M et al. Effect of buspirone on sexual dysfunction in depressed patients treated with selective serotonin reuptake inhibitors. J Clin Pharmacol 1999; 19 (3): 268–71. 67. LaPorta LD, Ware MR. Buspirone in the Treatment of Posttraumatic Stress Disorder. J Clin Pharmacol 1992; 12 (2): 133–4. 68. Lee ST, Park JH, Kim M. Efficacy of the 5‐HT1A Agonist, Buspirone Hydrochloride, in Migraineurs With Anxiety: A Randomized, Prospective, Parallel Group, Double‐Blind, Placebo‐Controlled Study. Headache: J Head Face Pain 2005; 45 (8): 1004–11. 69. Levy M et al. Treatment of agitation following traumatic brain injury: a review of the literature. NeuroRehabilitation 2005; 20 (4): 279–306. 70. Lilja JJ et al. Grapefruit juice substantially increases plasma concentrations of buspirone. Clin Pharmacol Ther 1998; 64 (6): 655–60. 71. Loane C, Politis M. Buspirone: what is it all about? Br Res 2012; 1461: 111–8. 72. Lohr JB et al. The clinical challenges of akathisia. CNS Spectrums 2015; 20: (S1): 1–16. 73. Lovenberg TW et al. A novel adenylyl cyclase-activating serotonin receptor (5-HT7) implicated in the regulation of mammalian circadian rhythms. Neuron 1993; 11 (3): 449–58. 74. Mahmood I, Sahajwalla C. Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug. Clin Pharmacokinet 1999; 36 (4): 277–87. 75. Malhotra S, Santosh PJ. An Open Clinical Trial of Buspirone in Children With Attention‐Deficit/Hyperactivity Disorder. J Am Acad Child Adolesc Psychiatry 1998; 37 (4): 364–71. 76. Markowitz JS et al. The psychostimulant d-threo-(R, R)-methylphenidate binds as an agonist to the 5HT1A receptor. Die Pharmazie – Int J Pharmaceutic Sci 2009; 64 (2): 123–5. 77. Masdrakis VG, Turic D, Baldwin DS. Pharmacological treatment of social anxiety disorder. Anxiety Dis Karger Publishers 2013; 29: 144–53. 78. McDougle CJ, Goodman WK, Leckman JF. Limited therapeutic effect of addition of buspirone in fluvoxamine-refractory obsessive-compulsive disorder. Am J Psychiatry 1993; 150: 647–9. 79. McDougle C. J., Goodman W. K., Price L. H. Dopamine antagonists in tic-related and psychotic spectrum obsessive compulsive disorder. J Clin Psychiatry 1994; 55: 24–31. 80. Milanlıoglu A. Paroxetine-induced severe sleep bruxism successfully treated with buspirone. Clinics 2012; 67 (2): 191–2. 81. Mitsikostas DD et al. Buspirone vs amitriptyline in the treatment of chronic tension‐type headache. Acta Neurol Scand 1997; 96 (4): 247–51. 82. Mohammadi MR et al. Buspirone versus Methylphenidate in the Treatment of Children with Attention-Deficit/Hyperactivity Disorder: Randomized Double-Blind Study. Acta Med Ir 2012; 50 (11): 723–8. 83. Mokhber N et al. Randomized, single‐blind, trial of sertraline and buspirone for treatment of elderly patients with generalized anxiety disorder. Psychiatr Сlin Neuroscienc 2010; 64 (2): 128–33. 84. Moss LE, Neppe VM, Drevets WC. Buspirone in the treatment of tardive dyskinesia. J Clin Psychopharmacol 1993; 13 (3): 204–9. 85. Munjack DJ et al. A pilot study of buspirone in the treatment of social phobia. J Anxiety Disorders 1991; 5 (1): 87–98. 86. Navinés R et al. Interaction between serotonin 5-HT1A receptors and b-endorphins modulates antidepressant response. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2008; 32 (8): 1804–9. 87. Onrust SV, McClellan K. Perospirone. CNS Drugs 2001; 15 (4): 329–37. 88. Othmer E, Othmer SC. Effect of buspirone on sexual dysfunction in patients with generalized anxiety disorder. J Clin Psychiatry 1987; 48 (5): 201–3. 89. Patterson JF. Akathisia associated with buspirone. J Clin Psychopharmacol 1988; 8 (4): 296–7. 90. Phillips KA. An open study of buspirone augmentation of serotonin-reuptake inhibitors in body dysmorphic disorder. Psychopharmacol Bull 1996; 32 (1): 175–80. 91. Phillips KA et al. Effectiveness of pharmacotherapy for body dysmorphic disorder: a chart-review study. J Clin Psychiatry 2001; 62 (9): 721–7. 92. Phillips KA, Hollander E. Treating body dysmorphic disorder with medication: evidence, misconceptions, and a suggested approach. Body Image 2008; 5 (1): 13–27. 93. Piškulić D et al. Treatment of cognitive dysfunction in chronic schizophrenia by augmentation of atypical antipsychotics with buspirone, a partial 5‐HT1A receptor agonist. Hum Psychopharmacol: Clin Exp 2009; 24 (6): 437–46. 94. Plassat JL, Amlaiky N, Hen R. Molecular cloning of a mammalian serotonin receptor that activates adenylate cyclase. Mol Pharmacol 1993; 44 (2): 229–36. 95. Poyurovsky M, Weizman A. Serotonergic agents in the treatment of acute neuroleptic-induced akathisia: open-label study of buspirone and mianserin. Int Clin Psychopharmacol 1997; 12 (5): 263–8. 96. Rajan R, Sun Y. Reevaluating Antidepressant Selection in Patients With Bruxism and Temporomandibular Joint Disorder. J Psychiatr Practice 2017; 23 (3): 173–9. 97. Rajewski A, Rybakowski F. Efficacy of buspirone and fluoxetine in short-term treatment of bulimia nervosa. Psychiatr Pol 2006; 40 (1): 75–82. 98. Reid TL. Treatment of generalized anxiety disorder and trichotillomania with buspirone. Am J Psychiatry 1992; 149 (4): 573–4. 99. Rickels K et al. Buspirone and diazepam in anxiety: a controlled study. J Clin Psychiatry 1982; 43 (12 Pt. 2): 81–6. 100. Rickels K et al. Buspirone in major depression: a controlled study. J Clin Psychiatry 1991; 52 (1): 34–8. 101. Robinson DS et al. Clinical effects of the 5-HT1A partial agonists in depression: a composite analysis of buspirone in the treatment of depression. J Clin Psychopharmacol 1990; 10 (Suppl. 3): 67S–76S. 102. Ross C. A. Buspirone in the treatment of tardive dyskinesia. Med Hypotheses 1987; 22 (3): 321–8. 103. Ruat M et al. Molecular cloning, characterization, and localization of a high-affinity serotonin receptor (5-HT7) activating cAMP formation. Proc Nat Acad Sci USA 1993; 90 (18): 8547–51. 104. Sabaawi M, Holmes TF, Fragala MR. Drug-induced akathisia: subjective experience and objective findings. Mil Med 1994; 159 (4): 286–91. 105. Şahin OS, Malas FÜ. Duloxetine-induced Sleep Bruxism in Fibromyalgia Successfully Treated With Amitriptyline. Acta Reumatol Port 2015; 40 (4): 391. 106. Schatzberg AF, Nemeroff CB. The American psychiatric publishing textbook of psychopharmacology. Am Psychiatric Pub 2009. 107. Schneier FR et al. Buspirone in social phobia. J Clin Psychopharmacol 1993; 13 (4): 251–6. 108. Schweizer EE et al. Open trial of buspirone in the treatment of major depressive disorder. Psychopharmacol Bull 1986; 22 (1): 183–5. 109. Sheehan DV et al. The relative efficacy of high‐dose buspirone and alprazolam in the treatment of panic disorder: a double‐blind placebo‐controlled study. Acta Psychiatr Scand 1993; 88 (1): 1–11. 110. Sheikhmoonesi F et al. A triple-blinded, randomized, placebo-controlled trial to examine the efficacy of buspirone added to typical antipsychotic drugs in patients with chronic schizophrenia. J Res Med Sci: Official J Isfahan Univer Med Sci 2015; 20 (2): 140–5. 111. Sramek JJ et al. Efficacy of buspirone in generalized anxiety disorder with coexisting mild depressive symptoms. J Clin Psychiatry 1996; 57 (7): 287–91. 112. Stahl SM. Stahl's essential psychopharmacology: neuroscientific basis and practical applications. Camb Univer Press 2013. 113. Stern TA et al. Massachusetts General Hospital Psychopharmacology and Neurotherapeutics E-Book. Elsevier Health Sci 2015. 114. Strand M. et al. A double-blind, controlled trial in primary care patients with generalized anxiety: a comparison between buspirone and oxazepam. J Clin Psychiatry 1990; 51: 40–5. 115. Sumiyoshi T et al. Effect of buspirone, a serotonin 1A partial agonist, on cognitive function in schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res 2007; 95 (1–3): 158–68.